UroGen Settles Patent Litigation with Teva, Extends JELMYTO Exclusivity to 2030
Event summary
- UroGen resolves patent litigation with Teva, granting a non-exclusive license for a generic version of JELMYTO starting September 15, 2030, if FDA-approved.
- Teva's ANDA for JELMYTO has not received tentative FDA approval as of the agreement.
- UroGen retains nearly all of JELMYTO's patent protection period, with exclusivity extending through April 15, 2027.
- The agreement preserves UroGen's intellectual property strength and reinforces the value of its RTGel technology.
The big picture
The settlement underscores UroGen's ability to defend its intellectual property while allowing controlled market entry for generics. This strategic move preserves JELMYTO's exclusivity and reinforces UroGen's position in the uro-oncology space. The agreement reflects broader trends in biotech patent litigation, where companies balance litigation costs against the value of extended market exclusivity.
What we're watching
- Regulatory Timelines
- Whether Teva's generic version of JELMYTO will receive FDA approval by the agreed license date in 2030.
- Market Competition
- How the delayed entry of Teva's generic version will impact JELMYTO's market share and pricing power.
- Intellectual Property Strategy
- The pace at which UroGen can leverage its RTGel technology for other innovative treatments.
Related topics